Royalty Pharma plc Payments for (Proceeds from) Other Investing Activities
Royalty Pharma plc (RPRX) reported Payments for (Proceeds from) Other Investing Activities of $317.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsForProceedsFromOtherInvestingActivities · last filed 2026-08-05
- Royalty Pharma plc payments for (proceeds from) other investing activities for the quarter ending 2025-12-31 was $0.00.
- Royalty Pharma plc payments for (proceeds from) other investing activities for the quarter ending 2025-09-30 was $0.00.
- Royalty Pharma plc payments for (proceeds from) other investing activities for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Royalty Pharma plc payments for (proceeds from) other investing activities for the quarter ending 2024-09-30 was -$1.00K.
- Royalty Pharma plc payments for (proceeds from) other investing activities for fiscal 2025 was $8.95M.
- Royalty Pharma plc payments for (proceeds from) other investing activities for fiscal 2024 was -$2.04M, a 200.05% decline from fiscal 2023.
- Royalty Pharma plc payments for (proceeds from) other investing activities for fiscal 2023 was $2.04M.
- Royalty Pharma plc payments for (proceeds from) other investing activities for fiscal 2022 was $0.00.
| Period end | Payments for (Proceeds from) Other Investing Activities 3 month | Payments for (Proceeds from) Other Investing Activities 6 month | Payments for (Proceeds from) Other Investing Activities 9 month | Payments for (Proceeds from) Other Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $317.00K 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $8.95M 10-K · filed 2026-02-11 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $8.95M 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $8.95M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$1.00K derived: sum of 2 quarters · filed 2026-02-11 | -$2.04M 10-K · filed 2026-02-11 | |
| 2024-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$2.04M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | -$2.04M 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $2.04M derived: sum of 2 quarters · filed 2026-02-11 | $2.04M 10-K · filed 2026-02-11 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-12 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |